Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

An Australian vote for pharma: a history of health reform

This article was originally published in Scrip

Executive Summary

Reform

 

Year

 

Government

 

Major changes

 

Medibank II

 

1976

 

Fraser coalition

 

Allowed people with private insurance to opt-out of Medibank and the compulsory 2.5% levy on taxable income.

 

Medibank III

 

1978

 

Fraser coalition

 

Abolished the Medibank levy.

Restored access to public hospitals for those without private health insurance and provided universal benefits (40% of scheduled fee) for medical services.

Made health insurance voluntary.

 

Medibank IV

 

1979

 

Fraser coalition

 

Abolished universal medical insurance except for expenses in excess of A$20.

 

Return to voluntary private health insurance

 

1981

 

Fraser coalition

 

Medibank abolished. Made government benefit of 30% of scheduled fee available to those with private health insurance.

Made a tax rebate of 32% available when private insurance was purchased.

 

Medicare

 

1984

 

Hawke Labor

 

Re-introduced universal, tax-funded insurance.

 

Subsidies to private health insurance reduced

 

1984–1996

 

Hawke-Keating Labor

 

Removed tax rebates and public subsidies for private health insurance and private hospitals.

Introduced contracts between private health insurance funds and hospitals and between funds and doctors in order to reduce patients' out-of-pocket payments.

 

Subsidies for private health insurance increased

 

1999–2007

 

Howard coalition

 

Increased Medicare levy for higher income earners without insurance.

Introduced subsidy for private health insurance premiums.

Enabled funds to charge higher premiums to people first taking out private health insurance after the age of 30.

Introduced a Medicare safety net that subsidised patient out-of-pocket expenses above threshold amount.

Enabled private health insurance funds to cover additional out of hospital services.

 

Pharmaceutical Benefits Scheme (PBS) reforms

 

Ongoing

 

Rudd/Gillard Labor

 

Split formulary into F1 and F2 with different pricing strategies for each.

Introduced three different types of statutory price reductions for drugs in F2.

The price disclosure programme singles out generics for further price cuts.

Saw further negotiations on 'therapeutic groups' and the establishment of the Access to Medicines Working Group (AMWG).

 

Therapeutic Goods Administration (TGA) reforms

 

Ongoing

 

Rudd/Gillard Labor

 

Includes the following three key initiatives:

(1) accelerate the application entry and improved application coordination (streamlined submission process);

(2) increase transparency of the prescription medicine regulatory process (the AusPAR project);

(3) improve access to prescription medicine information (the product information [PI]/consumer medicine information [CMI] project).

 

National Health and Hospitals Network (NHHN) reforms

 

Ongoing

 

Rudd/Gillard Labor

 

Under the NHHN, the Labor government aims to:

(1) reform the fundamentals of Australia's health and hospital system, including funding and governance, to provide a sustainable foundation for providing better services now and in the future;

(2) change the way health services are delivered, through better access to high quality integrated care designed around the needs of patients, and a greater focus on prevention, early intervention and the provision of care outside of hospitals;

(3) provide better care and better access to services for patients right now, through increased investments to provide better hospitals, better infrastructure, and more doctors and nurses.

 

You may also be interested in...



Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs

Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.

Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats

The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.

Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States

Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC010289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel